Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $12.27, for a total value of $24,540.00. Following the sale, the president now owns 2,932,467 shares in the company, valued at $35,981,370.09. The trade was a 0.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total value of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total value of $22,100.00.

Gyre Therapeutics Price Performance

Shares of NASDAQ:GYRE opened at $12.45 on Friday. The company’s fifty day moving average is $12.71 and its two-hundred day moving average is $12.64. Gyre Therapeutics, Inc. has a 1-year low of $8.26 and a 1-year high of $27.45.

Institutional Investors Weigh In On Gyre Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in shares of Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after purchasing an additional 43,840 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after purchasing an additional 90,557 shares during the period. State Street Corp grew its stake in Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after buying an additional 8,412 shares during the last quarter. Advantage Alpha Capital Partners LP bought a new position in Gyre Therapeutics during the 3rd quarter worth $334,000. Finally, WINTON GROUP Ltd acquired a new stake in Gyre Therapeutics in the second quarter worth $220,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.